2014 ASCO Annual Meeting

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.

ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

Prof Peeters talks to ecancertv at ASCO 2014 about the updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab plus FOLFIRI for second-line treatment of metastatic colorectal cancer.

Dr Pérol talks to ecancertv at ASCO 2014 about the findings from the REVEL phase III study of patients with stage IV non-small cell lung cancer (NSCLC), which indicate that a combination of a new anti-angiogenesis drug, ramucirumab, and standard docetaxel chemotherapy extends overall survival for patients who have a relapse after initial treatment, when compared to docetaxel plus placebo.

Prof Harrington talks to ecancertv at ASCO 2014 about a randomised phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma.

Dr Perez talks to ecancertv at ASCO 2014 about the findings from a large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) which suggest that post-surgery (adjuvant) treatment using a combination of two HER2-targeted drugs – trastuzumab and lapatinib – is no more effective than standard treatment with trastuzumab alone for women with early HER2-positive breast cancer.

Prof Thomas Powles (Barts Health, London, UK) discusses the use of the drug MPDL3280A to inhibit the protein PD-L1 in patients with metatastatic urothelial bladder cancer.

Dr Byrd talks to ecancertv at ASCO 2014 about the early findings from the phase III RESONATE study which indicate that ibrutinib yields lasting tumour responses and marked improvement in survival over standard of atumumab for patients with relapsed chronic lymphocytic leukaemia (CLL).

Dr Hinrichs talks to ecancertv at ASCO 2014 about his work using immunotherapy to tackle cervical cancer. HPV-targeted tumour-infiltrating lymphocytes for the treatment of cervical cancer is a new field.

Prof Schlumberger talks to ecancertv at ASCO 2014 about the results of the phase three SELECT trial, which was a multicentre, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131 radioiodine-refractory differentiated thyroid cancer (RR-DTC).

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the results from an expanded phase I study which showed that concurrent treatment with immunotherapy drugs ipilimumab and nivolumab produces an increased median survival of roughly three and a half years (40 months) for patients with advanced melanoma.

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the final analysis on the impact of ipilimumab on relapse-free survival from a randomised phase III study, EORTC 18071, which indicates that adjuvant (post-surgery) therapy with ipilimumab for patients with high-risk stage III melanoma decreases the relative risk of cancer recurrence by roughly 25 percent compared to placebo.

Prof Sznol talks to ecancertv at ASCO 2014 about the results from an expanded phase I study which show that concurrent treatment with immunotherapy drugs ipilimumab and nivolumab produces an unprecedented median survival of roughly three and a half years (40 months) for patients with advanced melanoma.

Dr Pagani talks to ecancertv at ASCO 2014 about the results of a landmark study that was a joint analysis of two phase III trials, TEXT and SOFT, which demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when given with ovarian function suppression in premenopausal women with hormone-sensitive cancers.

Prof Sweeney talks to ecancertv at ASCO 2014 about the findings from a federally funded phase III study, E3805, which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.

Dr Liu talks to ecancertv at ASCO 2014 about the findings from a federally funded, NCI-sponsored phase II study which suggest that the combination of two investigational oral drugs, the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib, is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.

Prof Peeters talks to ecancertv at ASCO 2014 about the results of the results from a large federally funded phase III study demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cancer and no KRAS mutations.